Nov 09, 2022 / 06:45PM GMT
Mitra Ramgopal - Sidoti & Company - Analyst
Okay. Good afternoon, everyone, and welcome to the Sidoti November Micro-Cap Virtual Conference. My name is Mitra Ramgopal. I'll be the host for our next presenter, Akari Therapeutics. Representing the company today is CEO, Rachelle Jacques. All in, it's 30 minutes and there will be some time for Q&A at the end. So, if you have any questions, please type them in the Q&A tab. I'll try to relay as many as possible.
With that, I'd like to hand it over to Rachelle.
Rachelle Jacques - Akari Therapeutics, Plc - President, CEO
Thank you, Mitra, and welcome, everybody. Thank you for your interest in Akari Therapeutics. This is our company presentation, and we're looking forward to sharing with you a bit about what we're doing.
We will be making some forward-looking statements. I hope you're familiar with the disclosures here. So, just to keep that in mind as we go through.
Our lead asset is called nomacopan. And this is a bispecific biologic. It's a recombinant protein with two modes of
Akari Therapeutics PLC at Sidoti & Company November Micro Cap Virtual Conference Transcript
Nov 10, 2022
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers